Nanospectra Biosciences
Commercialization of a unique nanotechnology-based cancer therapy that allows focused ablation of tumors without damage to healthy tissue.
- Stage Full Product Ready
- Industry Medical Devices and Equipment
- Location Houston, TX, USA
- Currency USD
- Founded March 2002
- Employees 8
- Website nanospectra.com
Company Summary
Nanospectra (NBI) is commercializing a particle-based therapy for the precise thermal destruction of solid cancer tumors. By allowing the systemically delivered particles to determine the zones of ablation (rather than the placement of an energy source), AuroLase® Therapy can thermally ablate irregularly shaped or inoperable tumors while eliminating damage to healthy adjacent tissue and preserving nearby critical structures.
Team
-
David K JordenInterim President and CEO
-
Glenn P GoodrichVice President, COO
Dr. Goodrich has been with Nanospectra since 2005. He holds a BS in Chemistry and a BA in Computer Science from The University of Iowa and a PhD in Chemistry from Penn State University. He has extensive experience with fabrication and application of nanoparticies, having worked in the field in graduate school and as a post-doctoral fellow under Dr. Naomi Halas at Rice University.
-
Jon SchwartzDirector, Clinical Research, PhD
Dr. Schwartz has been with Nanospectra since 2005. He holds a BS and a MS in Electrical Engineering from Rice University and a PhD in Biophysics from The University of Texas Graduate School of Biomedical Science. He is responsible for the conduct of Nanospectra's clinical pilot studies for the treatment of human cancers. Dr. Schwartz' primary area of research is the development of minimally-invasive tumor ablation techniques using nanoparticles a
Advisors
-
Kendall, Koenig & OelsnerLawyerUnconfirmedDon PayneAccountantUnconfirmed
Previous Investors
-
Yellowstone CapitalUnconfirmedSentinel Trust CompanyUnconfirmed
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.